US 12,188,098 B2
Pancreatic cancer detection kit or device, and detection method
Junpei Kawauchi, Kamakura (JP); Hitoshi Nobumasa, Kamakura (JP); Satoko Kozono, Kamakura (JP); Satoshi Kondou, Kamakura (JP); Hiroko Sudo, Kamakura (JP); Atsushi Ochiai, Kashiwa (JP); and Motohiro Kojima, Kashiwa (JP)
Assigned to Toray Industries, Inc., Tokyo (JP); and National Cancer Center, Tokyo (JP)
Filed by TORAY INDUSTRIES, INC., Tokyo (JP); and NATIONAL CANCER CENTER, Tokyo (JP)
Filed on Sep. 7, 2023, as Appl. No. 18/463,079.
Application 18/463,079 is a division of application No. 17/114,210, filed on Dec. 7, 2020, granted, now 11,788,150.
Application 17/114,210 is a division of application No. 16/452,269, filed on Jun. 25, 2019, granted, now 10,920,282, issued on Feb. 16, 2021.
Application 16/452,269 is a continuation of application No. 15/314,859, granted, now 10,370,722, issued on Aug. 6, 2019, previously published as PCT/JP2015/065696, filed on May 29, 2015.
Claims priority of application No. 2014-113523 (JP), filed on May 30, 2014; and application No. 2014-185730 (JP), filed on Sep. 11, 2014.
Prior Publication US 2024/0011104 A1, Jan. 11, 2024
Int. Cl. C07H 21/02 (2006.01); C12M 1/00 (2006.01); C12M 1/34 (2006.01); C12N 15/09 (2006.01); C12Q 1/6886 (2018.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01); G01N 37/00 (2006.01)
CPC C12Q 1/6886 (2013.01) [C12M 1/00 (2013.01); C12M 1/34 (2013.01); C12N 15/09 (2013.01); G01N 33/53 (2013.01); G01N 33/574 (2013.01); G01N 37/00 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)] 5 Claims
 
1. A method for detecting pancreatic cancer in a human subject, comprising:
(a) measuring an expression level of hsa-miR-4665-5p in a blood, serum or plasma sample from the subject:
(b) comparing the measured expression level of hsa-miR-4665-5p with a control expression level obtained from a healthy subject:
(c) detecting a decreased expression level of hsa-miR-4665-5p in the sample from the subject as compared to the control expression level,
wherein the decreased expression level of hsa-miR-4665-5p indicates that the subject has pancreatic cancer; and
(d) treating the subject for pancreatic cancer or performing a diagnostic procedure on the subject,
wherein the treatment comprises surgery, radiotherapy, chemotherapy or a combination thereof, and
wherein the diagnostic procedure comprises abdominal ultrasonography, CT scanning, endoscopic retrograde cholangiopancreatography, or endoscopic ultrasonography, or a combination thereof.